<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recently, prothrombin gene mutation G20210A has been associated with elevated <z:mp ids='MP_0005048'>thrombosis</z:mp> risk and rarely with <z:hpo ids='HP_0005305'>cerebral vein thrombosis</z:hpo> (CVT) </plain></SENT>
<SENT sid="1" pm="."><plain>Three patients are described who had this genetic predisposition and who developed CVT in an unusual constellation with other factors </plain></SENT>
<SENT sid="2" pm="."><plain>In the first patient, the intake of <z:chebi fb="0" ids="39867">valproic acid</z:chebi> (VPA) may have played an aggravating role in the development of CVT; in the second patient diagnosis of <z:e sem="disease" ids="C0005779" disease_type="Disease or Syndrome" abbrv="">coagulation disorder</z:e> was made during pregnancy consultation 6 years after CVT; in the third patient the CVT occurred at the age of 78 years </plain></SENT>
<SENT sid="3" pm="."><plain>In patients with CVT, coagulation-examinations should include tests for the prothrombin gene (G20210A) mutation </plain></SENT>
</text></document>